Abhay Joshi
2018
In 2018, Abhay Joshi earned a total compensation of $2.2M as Chief Operating Officer at Revance Therapeutics, a 11% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $232,186 |
|---|---|
| Option Awards | $1,192,465 |
| Salary | $469,062 |
| Stock Awards | $342,513 |
| Other | $9,210 |
| Total | $2,245,436 |
Joshi received $1.2M in option awards, accounting for 53% of the total pay in 2018.
Joshi also received $232.2K in non-equity incentive plan, $469.1K in salary, $342.5K in stock awards and $9.2K in other compensation.
Rankings
In 2018, Abhay Joshi's compensation ranked 5,132nd out of 14,244 executives tracked by ExecPay. In other words, Joshi earned more than 64.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,132 out of 14,244 | 64th |
Division Manufacturing | 1,934 out of 5,759 | 66th |
Major group Chemicals And Allied Products | 708 out of 2,122 | 67th |
Industry group Drugs | 592 out of 1,811 | 67th |
Industry Pharmaceutical Preparations | 455 out of 1,385 | 67th |
Source: SEC filing on March 25, 2019.
Joshi's colleagues
We found six more compensation records of executives who worked with Abhay Joshi at Revance Therapeutics in 2018.
2018
L Browne
Revance Therapeutics
Chief Executive Officer
2018
Caryn McDowell
Revance Therapeutics
General Counsel
2018
Tobin Schilke
Revance Therapeutics
Chief Financial Officer
2018
Todd Zavodnick
Revance Therapeutics
Former Chief Commercial Officer and President, Aesthetics & Therapeutics
2018
Lauren Silvernail
Revance Therapeutics
Chief Financial Officer
2018
Cyril Allouche
Revance Therapeutics
Former Head of Finance and Corporate Controller, Principal Accounting Officer
News
Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
March 24, 2022
Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
March 11, 2021
Revance Therapeutics CEO Mark Foley receives $17M in 2019
March 26, 2020
Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
March 25, 2019